• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Companies prepare to unveil research at ARVO 2024 conference


More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.

(Image Credit: AdobeStock/wellphoto)

(Image Credit: AdobeStock/wellphoto)

With less than a week until one of ophthalmology’s biggest conferences of the year, companies and organizations are eagerly sharing information about the data and pipeline updates they plan to provide at the ARVO 2024 meeting.

Editor’s note: The following list is non-exhaustive, and lists companies in alphabetical order.

Avirmax Biopharma Inc.

Shengjiang Liu, PhD, Chief Executive and Scientific Officer for Avirmax Biopharma Inc., will be presenting "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells" during the developing gene therapy for glaucoma neuroprotection: Opportunities and challenges symposium on May 9, 8 – 10 am PT.1

The company will have two additional presentations. The first is, “Novel AAV2 capsid expressing Aflibercept shows efficacy and sustainability in rabbit DL-AAA model,” presented by Sameera Peraramelli, PhD, on May 9, 2024, from 11:45 am to 1:30 pm PT. The second will be “Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys,” presented by Shengjiang Liu, PhD, on May 8, 2024, from 2:15 pm to 4:00 pm PT.1

Bausch + Lomb

Bausch + Lomb Corporation has announced that they will have 21 poster presentations at the upcoming ARVO 2024 conference in Seattle, Washington. Their posters will showcase results from studies evaluating consumer, pharmaceutical, surgical, and vision care products as well as pipeline updates. Among the topics is the novel daily nutritional supplement formulated for dry eye symptoms.2

See the full list of posters presented by Bausch + Lomb.

Doheny and UCLA Stein Eye Institute

The Doheny Eye Institute will have more than 25 scientists and clinician-scientists presenting at the ARVO annual meeting. Among these presentations, Deborah A. Ferrington, PhD, Chief Scientific Officer at Doheny Eye Institute, will present a mini-symposium session on the topic, “Genotype-Specific Differences in Mitochondrial Function Specific to the CFH Y402H Risk Allele Associated with AMD.” This will take place May 9, 2024, from 2:45 p.m. until 3:00 pm PT.3

View a complete list and schedule for all of the Doheny Eye Institute and UCLA Stein Eye Institute research presentations.


eyeDNA (a subsidiary of Coave Therapeutics), will share a presentation on retinitis pigmentosa during the ARVO 2024 meeting. Jean-Baptiste Ducloyer, MD, Nantes University Department of Ophthalmology, France, will deliver the talk, “12-month Safety and Efficacy Evaluation of HORA-PDE6B, a Gene Therapy Targeting Patients with Retinitis Pigmentosa Due to Biallelic PDE6B Gene Mutation.” This presentation will take place Monday, May 6, 2024; 3:30 PM – 3:45 pm PT.4


On Tuesday, May 7, 2024 at 3:30 – 5:15 pm PT, Eyenovia will present “Evaluation of APNT™ Nanoparticle Formulation in Ophthalmic Medications.” This event will detail results from a study demonstrating that Formosa Pharmaceuticals’ Active Pharmaceutical ingredient Nanoparticle Technology (APNT) can improve solubility and bioavailability of topical ophthalmic medications.5

Kyowa Kirin

Kyowa Kirin Co., Ltd. (TSE: 4151), a Japan-based global specialty pharmaceutical company, will share pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD) at ARVO 2024. The presentation, titled Pre-clinical ocular pharmacokinetics and efficacy of a novel Tivozanib eye drop for neovascular age-related macular degeneration,” will take place on Wednesday, May 8, at 2:15 – 4:00 pm PT.6


At the annual ARVO meeting, Ocugen will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial).7

Click for presentation titles, locations, and times.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. will present positive long-term results and subgroup analyses from the pivotal clinical program of aflibercept 8 mg at ARVO 2024. The presentations are part of 14 accepted abstracts on aflibercept 8 mg and aflibercept 2 mg injections.8

In the company’s press release8, 3 podium presentations around this topic were highlighted:

  • One-year (48 week) data from the PHOTON trial investigating EYLEA HD in diabetic macular edema (DME) patients with or without prior treatment, compared to EYLEA.
  • Two-year (96 week) results from the PULSAR trial investigating EYLEA HD in patients with wet age-related macular degeneration (wAMD), compared to EYLEA, which will feature a post-hoc analysis on the correlation of key baseline disease characteristics in wAMD to dosing intervals of EYLEA HD.
  • A PULSAR subgroup analysis evaluating visual and anatomic improvements with EYLEA HD, compared to EYLEA, based on baseline best corrected visual acuity (BCVA), corneal refractive therapy (CRT), choroidal neovascularization (CNV) type and race.

View full list of 14 abstracts

SalioGen Therapeutics

SalioGen Therapeutics will give a poster presentation on “ABCA4 gene replacement in a mouse model of Stargardt disease using a mammalian transposon system,” at the ARVO 2024 conference. This will take place in the exhibit hall on Monday, May 6 from 3:00-4:45 pm PT.9

Stuart Therapeutics Inc.

Members of the Stuart Therapeutics Inc. Research and Development team co-authored a poster presentation entitled, “"Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation.” The work for this presentation was conducted at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform to understand its efficacy in reversing the disruption of scleral collagen in the eye.10

Unity Biotechnology

Unity Biotechnology will present 2 poster presentations at ARVO 2024. The first is “Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate for Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up.” This will be presented by Dante Joseph Pieramici, MD, from California Retina Consultants on May 6 at 8:30-10:15 am PT. The second presentation is, Senolytic drug candidate in wet AMD demonstrates benefit with Multifocal ERG testing.” This will be presented by Raj K. Maturi, MD, from Midwest Eye Institute on May 8 at 2:25-4:00 pm PT.11

In addition to the information above, Modern Retina covered earlier company announcements in a previous article.

  1. Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle. Published April 1, 2024. Accessed April 29, 2024. https://www.prnewswire.com/news-releases/avirmax-biopharma-inc-to-present-at-the-2024-arvo-annual-meeting-in-seattle-302104758.html
  2. Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting. Bausch + Lomb. Published April 29, 2024. Accessed April 29, 2024. https://www.bausch.com/news/?id=208
  3. Doheny Eye Institute Announces Upcoming Presentations at ARVO 2024 Annual Meeting. Doheny Eye Institute. Published April 24, 2024. Accessed April 24, 2024. https://www.globenewswire.com/news-release/2024/04/24/2868672/0/en/Doheny-Eye-Institute-Announces-Upcoming-Presentations-at-ARVO-2024-Annual-Meeting.html
  4. eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting. Coave Therapeutics. Published April 25, 2024. Accessed April 29, 2024.
  5. Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension. Eyenovia, Inc. Published April 25, 2024. Accessed April 29,2024. https://www.globenewswire.com/news-release/2024/04/25/2869465/0/en/Eyenovia-Provides-Clinical-and-Scientific-Update-on-FDA-Approved-Products-Mydcombi-and-Clobetasol-Propionate-Ophthalmic-Suspension.html
  6. Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024. Kyowa Kirin. Published April 2, 2024. Accessed April 29, 2024. https://www.prnewswire.com/news-releases/kyowa-kirin-announces-acceptance-of-abstract-for-presentation-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting-2024-302106101.html
  7. UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting. Ocugen Inc. Published April 26, 2024. Accessed April 29, 2024. https://www.globenewswire.com/news-release/2024/04/26/2870525/0/en/UPDATE-Ocugen-to-Present-on-Modifier-Gene-Therapy-Platform-at-Association-for-Research-in-Vision-and-Ophthalmology-2024-Annual-Meeting.html
  8. EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases. Published April 29, 2024. Accessed April 29, 2024. https://www.globenewswire.com/news-release/2024/04/29/2871070/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Presentations-at-ARVO-Reinforce-Sustained-and-Clinically-Meaningful-Outcomes-in-Serious-Retinal-Diseases.html
  9. SalioGen Therapeutics Announces Data Presentations at 2024 Annual Meetings for the Association for Research in Vision and Ophthalmology (ARVO) and American Society of Gene & Cell Therapy (ASGCT). SalioGen Therapeutics. Published April 22, 2024. Accessed April 29, 2024. https://www.prnewswire.com/news-releases/saliogen-therapeutics-announces-data-presentations-at-2024-annual-meetings-for-the-association-for-research-in-vision-and-ophthalmology-arvo-and-american-society-of-gene--cell-therapy-asgct-302123770.html
  10. Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024. Published April 19, 2024. Accessed April 29, 2024. https://www.prnewswire.com/news-releases/stuart-therapeutics-inc-announces-upcoming-presentations-at-arvo-2024-302122140.html
  11. Unity biotechnology announces upcoming presentations at the ARVO 2024 annual meeting. Unity Biotechnology. Published April 25, 2024. Accessed April 25, 2024. https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-upcoming-presentations-arvo-2024
Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.